Page last updated: 2024-12-05

dilactide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dilactide is a cyclic dimer of lactic acid. It is a biodegradable and biocompatible polymer that has been extensively studied for its potential applications in biomedical engineering. Dilactide can be synthesized by dehydration of lactic acid or by ring-opening polymerization of lactide. Dilactide has been shown to have good mechanical properties and is used in the production of biodegradable polymers, such as polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA). Dilactide has been studied for a wide range of applications, including drug delivery, tissue engineering, and medical devices. Its biodegradability and biocompatibility make it an attractive material for these applications. Dilactide is often studied in conjunction with other polymers to create materials with specific properties for different applications.'

dilactide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7272
CHEMBL ID3185272
CHEBI ID177651
SCHEMBL ID15034
MeSH IDM0242658

Synonyms (59)

Synonym
CHEBI:177651
dl-lactide
p-dioxane-2,5-dione, 3,6-dimethyl-
1,4-dioxane-2,5-dione, 3,6-dimethyl-
dilactide
nsc 403080
ai3-05059
einecs 202-468-3
3,6-dimethyl-2,5-dioxo-1,4-dioxane
propanoic acid, 2-hydroxy-, bimol. cyclic ester
lactic acid, bimol. cyclic ester
1,5-dione, 3,6-dimethyl-
3,5-dioxo-1,4-dioxane
95-96-5
nsc-403080
nsc403080
propanoic acid, bimol. cyclic ester
p-dioxane-2, 3,6-dimethyl-
lactide
3,6-dimethyl-1,4-dioxane-2,5-dione
L0091
dl-dilactide
26680-10-4
dtxcid5021253
NCGC00255679-01
dtxsid7041253 ,
tox21_302164
cas-95-96-5
A826719
AKOS005206744
3,6-dimethyl-[1,4]dioxane-2,5-dione
33135-50-1
ec 202-468-3
7eh08mwo6m ,
unii-7eh08mwo6m
FT-0625454
FT-0601997
2,5-dimethyl-3,6-dioxo-1,4-dioxane
3,6-dimethyl-p-dioxane-2,5-dione
rac-lactide
dimethylglycolide
lactide, dl-
SCHEMBL15034
CHEMBL3185272
mfcd00082566
mfcd00011685
dl-3,6-dimethyl-1,4-dioxane-2,5-dione
l-3,6-dimethyl-1,4-dioxane-2,5-dione
lactid
Q421313
SY060845
AS-17933
purasorb dl; dl-dilactide; rac-lactide
hexythlazox
BCP34367
SY026985
D81885
EN300-1180042
SY062065

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"To evaluate the occurrence of adverse events and inflammatory reactions related to the use of biodegradable anchors."( Adverse events associated with biodegradable lactide-containing suture anchors.
Barber, FA; Cobaleda Aristizabal, AF; Sanders, EJ, 2014
)
0.4
" A shoulder procedure after the index operation was considered an adverse event."( Adverse events associated with biodegradable lactide-containing suture anchors.
Barber, FA; Cobaleda Aristizabal, AF; Sanders, EJ, 2014
)
0.4
" Adverse events (reoperations) were identified in 18 of 360 patients (5%): 13 tendon repairs and 5 labral/instability repairs."( Adverse events associated with biodegradable lactide-containing suture anchors.
Barber, FA; Cobaleda Aristizabal, AF; Sanders, EJ, 2014
)
0.4
"Anchor-specific adverse events occurred in 2 of 360 procedures (0."( Adverse events associated with biodegradable lactide-containing suture anchors.
Barber, FA; Cobaleda Aristizabal, AF; Sanders, EJ, 2014
)
0.4
" Cypermethrin, the chosen pesticide, contaminates the aquatic environment after being washed off from the agricultural field to nearby water bodies leading to biomagnification-related perturbation of the ecological balance and overall environmental health by elevating adverse effects on non-target organisms producing toxic metabolites through biotransformation."( Poly lactide-co-glycolide encapsulated nano-curcumin promoting antagonistic interactions between HSP 90 and XRCC1 proteins to prevent cypermethrin-induced toxicity: An in silico predicted in vitro and in vivo approach.
Bera, M; Dey, R; Dey, S; Majumder, A; Nandi, S; Samadder, A; Sow, P, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
"The application of baicalein (BE) in central nervous system (CNS) neurodegenerative diseases is hampered by its poor solubility and low oral bioavailability despite its neuroprotective effects."( Poly (ethylene glycol)-block-poly (D, L-lactide) (PEG-PLA) micelles for brain delivery of baicalein through nasal route for potential treatment of neurodegenerative diseases due to oxidative stress and inflammation: An in vitro and in vivo study.
Ho, PC; Huang, L; Yang, S; Zhang, L, 2020
)
0.56
" However, since the absorption rate is slow, it is necessary to keep in mind its long-term radiographic detectability and the possibility of late-onset granuloma."( Clinical Evaluation of Unsintered Hydroxyapatite Particles/Poly L-Lactide Composite Device in Craniofacial Surgery.
Hashikawa, K; Naruse, H; Osawa, S; Terashi, H, 2021
)
0.62
" The pleiotropic effects of statins have been well described in many in vitro and in vivo studies, but these effects are difficult to achieve in clinical practice due to the low bioavailability of statins and their first-pass metabolism in the liver."( Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS).
Basinska, T; Czuczwar, S; Dabrowski, W; Gadzinowski, M; Kocki, J; Oru, N; Slomkowski, S; Szumilo, J; Vicaut, E; Wacinski, J; Wacinski, P, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Thus, these polymeric nanoparticles are promising vehicles for solid tumour drug delivery applications, offering greater tumour exposure while eliminating the need for toxic solvents and surfactants in the dosing formulation."( Amphiphilic micelles of poly(2-methyl-2-carboxytrimethylene carbonate-co-D,L-lactide)-graft-poly(ethylene glycol) for anti-cancer drug delivery to solid tumours.
Al-awar, RS; Aman, AM; Ho, KS; Shoichet, MS, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dioxanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.32560.000229.305416,493.5996AID743075; AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (337)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (0.59)18.2507
2000's21 (6.23)29.6817
2010's218 (64.69)24.3611
2020's96 (28.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.04 (24.57)
Research Supply Index5.84 (2.92)
Research Growth Index6.24 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.58%)5.53%
Reviews20 (5.85%)6.00%
Case Studies2 (0.58%)4.05%
Observational0 (0.00%)0.25%
Other318 (92.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]